MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

HQY

95.86

+2.98%↑

TLRY

1.48

-5.73%↓

Search

Natera Inc

Fermé

SecteurSoins de santé

186.56 -1.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

185.17

Max

190.04

Chiffres clés

By Trading Economics

Revenu

-34M

-101M

Ventes

45M

547M

Marge bénéficiaire

-18.467

Employés

4,424

EBITDA

-33M

-90M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+13.97% upside

Dividendes

By Dow Jones

Prochains Résultats

10 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.3B

24B

Ouverture précédente

187.62

Clôture précédente

186.56

Score Technique

By Trading Central

Confiance

Bullish Evidence

Natera Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 oct. 2025, 23:55 UTC

Actions en Tendance

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct. 2025, 23:49 UTC

Résultats

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct. 2025, 21:40 UTC

Résultats

Waste Connections 3Q Revenue Rises

21 oct. 2025, 21:14 UTC

Résultats
Principaux Mouvements du Marché

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct. 2025, 21:05 UTC

Acquisitions, Fusions, Rachats

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct. 2025, 20:57 UTC

Acquisitions, Fusions, Rachats

DraftKings to Launch Prediction Markets Platform

21 oct. 2025, 20:38 UTC

Résultats

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct. 2025, 20:35 UTC

Résultats

Capital One 3Q Sales, Profit Jump

21 oct. 2025, 20:32 UTC

Résultats

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct. 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 oct. 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct. 2025, 23:39 UTC

Market Talk

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct. 2025, 23:36 UTC

Market Talk

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre Says This Forms Part of Capital Management Strategy

21 oct. 2025, 22:55 UTC

Acquisitions, Fusions, Rachats

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct. 2025, 22:54 UTC

Acquisitions, Fusions, Rachats

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct. 2025, 21:09 UTC

Market Talk
Résultats

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct. 2025, 20:58 UTC

Market Talk
Résultats

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

21 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Financial Services Roundup: Market Talk

21 oct. 2025, 20:43 UTC

Résultats

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct. 2025, 20:41 UTC

Résultats

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct. 2025, 20:29 UTC

Résultats

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparaison

Variation de prix

Natera Inc prévision

Objectif de Prix

By TipRanks

13.97% hausse

Prévisions sur 12 Mois

Moyen 207.07 USD  13.97%

Haut 268 USD

Bas 175 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

17 ratings

16

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

153.79 / N/ASupport & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.
help-icon Live chat